A focused neurotechnology company advancing precision neurostimulation

Cortigent is developing precision neurostimulation technology, a type of brain-computer interface (BCI), to address critical unmet needs in artificial vision and motor recovery following stroke.

Who we are

Developing smart technology to interface with the brain’s surface

Cortigent develops systems designed to deliver precisely and independently controlled electrical micro-pulses to selected areas of the cortex (brain surface).

Our precision neurostimulation technology platform supports two new medical devices in development: the Orion® Visual Cortical Prosthesis System and the Stroke Recovery System.

Cortigent’s work is supported by an extensive intellectual property portfolio.

PlatformDynamic software control of electrical micro-pulses delivered through a multi-electrode surface array.

VisionOrion is being developed to create useful visual perception for people with profound blindness.

Motor recoveryThe Stroke Recovery System is being developed for use alongside rehabilitation after stroke.

Orion combines wearable, external and implanted components with a cortical-surface electrode array.

Company at a glance

One precision neurostimulation technology platform

PrecisionPrecisely and independently controlled electrical micro-pulses.

Surface arrayElectrodes placed on the brain’s surface, not within brain tissue.

Two devicesArtificial vision and post-stroke motor recovery in development.

ExperienceMedical-device, neuroscience and commercialization backgrounds.

Shared technology behind both devices

The implant, wireless communication, external processing and stimulation software form a common foundation that can be adapted to different areas of the cortex.

Explore the technology See the programs

Close view of the Cortigent electrode array

Company highlights

Cortigent brings together clinical experience, patented technology and commercial experience in neurostimulation.

Clinical foundation

Six years

Recently completed U.S. Early Feasibility Study follow-up for cortical neurostimulation.

Commercial experience

350+ implants

Historical Argus II experience contributed to Cortigent’s current platform.

Intellectual property

Patent portfolio

An extensive portfolio of issued patents covering neurotechnology inventions.

Market opportunity

$10B+

Combined estimated U.S. total addressable market across the two medical device programs.

Continue exploring

Three core pillars of the company story

People

Leadership

Meet the executives, scientists and directors bringing medical-device development, neuroscience and commercialization experience to Cortigent.

View leadership

Experience

Technology Legacy

See how Argus II and Second Sight Medical Products experience informed the current platform.

View history

Progress

Clinical Development

Review the recently completed Orion study and Cortigent’s planned development path.

View clinical development